Orbimed Advisors Llc Buys Neurocrine Biosciences Inc, Teva Pharmaceutical Industries, Endo International PLC, Sells Biogen Inc, Celgene Corp, Allergan PLC

• New Purchases: TEVA, ENDP, PRTA, CDNA, CBAY, ENTA, AUPH, TAK, MRSN, ADVM, SPRO, MNLO, KALV, KRYS,
• Added Positions: NBIX, EW, MGTX, BMY, MYOK, APLS, DCPH, MYL, ISRG, ABT, NTRA, AMRN, PRQR, MRK, SRPT, ANTM, EHTH, BHC, A, FOLD, SELB, TMO, ALPN, CLVS, HUM,
• Reduced Positions: BIIB, CELG, CI, VRTX, AERI, ARGX, WMGI, INSP, PBYI, SYK, TNDM, IMMU, HRTX, ALXN, ZLAB, ASND, NVTA, ILMN, RYTM, REGN, BOLD, AVRO, MRNS, REPH, SRRA,
• Sold Out: AGN, CVS, CNC, UNH, BLUE, MOH, IRWD, DVA, PFE, SPPI, ACIU, THC, HCA, ALLK, DERM, ICPT, SAGE, ECOR, RMED, MDCO, AFMD, RDHL, ALIM,

For the details of ORBIMED ADVISORS LLC's stock buys and sells, go to https://www.gurufocus.com/guru/orbimed+advisors+llc/current-portfolio/portfolio

1. Ascendis Pharma A/S (ASND) - 3,970,673 shares, 7.90% of the total portfolio. Shares reduced by 2.86%
2. Tricida Inc (TCDA) - 10,889,280 shares, 7.11% of the total portfolio.
3. Clementia Pharmaceuticals Inc (CMTA) - 10,425,225 shares, 4.60% of the total portfolio.
4. Alexion Pharmaceuticals Inc (ALXN) - 1,957,200 shares, 4.47% of the total portfolio. Shares reduced by 4.41%
5. Boston Scientific Corp (BSX) - 5,790,400 shares, 3.76% of the total portfolio.

Orbimed Advisors Llc initiated holding in Teva Pharmaceutical Industries Ltd. The purchase prices were between $15.42 and $20.01, with an estimated average price of $17.62. The stock is now traded at around $11.62. The impact to a portfolio due to this purchase was 1.08%. The holding were 4,079,000 shares as of .

Orbimed Advisors Llc initiated holding in Endo International PLC. The purchase prices were between $7.3 and $11.24, with an estimated average price of $9.39. The stock is now traded at around $6.30. The impact to a portfolio due to this purchase was 0.84%. The holding were 6,165,464 shares as of .

Orbimed Advisors Llc initiated holding in Prothena Corp PLC. The purchase prices were between $10.3 and $14.49, with an estimated average price of $12.45. The stock is now traded at around $9.29. The impact to a portfolio due to this purchase was 0.5%. The holding were 2,435,278 shares as of .

Orbimed Advisors Llc initiated holding in CareDx Inc. The purchase prices were between $22.09 and $39.21, with an estimated average price of $28.96. The stock is now traded at around $33.46. The impact to a portfolio due to this purchase was 0.44%. The holding were 827,600 shares as of .

Orbimed Advisors Llc initiated holding in CymaBay Therapeutics Inc. The purchase prices were between $7.87 and $13.42, with an estimated average price of $10.56. The stock is now traded at around $12.59. The impact to a portfolio due to this purchase was 0.42%. The holding were 1,874,955 shares as of .

Orbimed Advisors Llc initiated holding in Enanta Pharmaceuticals Inc. The purchase prices were between $69.08 and $105.66, with an estimated average price of $89.42. The stock is now traded at around $92.82. The impact to a portfolio due to this purchase was 0.38%. The holding were 233,100 shares as of .

Orbimed Advisors Llc added to a holding in Neurocrine Biosciences Inc by 270.94%. The purchase prices were between $69.31 and $91.53, with an estimated average price of $83.53. The stock is now traded at around $79.86. The impact to a portfolio due to this purchase was 1.99%. The holding were 1,833,200 shares as of .

Orbimed Advisors Llc added to a holding in Edwards Lifesciences Corp by 53.57%. The purchase prices were between $143.66 and $192.15, with an estimated average price of $170.98. The stock is now traded at around $172.79. The impact to a portfolio due to this purchase was 0.81%. The holding were 715,000 shares as of .

Orbimed Advisors Llc added to a holding in MeiraGTx Holdings PLC by 423.51%. The purchase prices were between $9.2 and $21.21, with an estimated average price of $13.93. The stock is now traded at around $24.09. The impact to a portfolio due to this purchase was 0.58%. The holding were 2,460,251 shares as of .

Orbimed Advisors Llc added to a holding in Bristol-Myers Squibb Company by 136.21%. The purchase prices were between $45.12 and $53.8, with an estimated average price of $49.88. The stock is now traded at around $47.76. The impact to a portfolio due to this purchase was 0.55%. The holding were 1,195,000 shares as of .

Orbimed Advisors Llc added to a holding in MyoKardia Inc by 170.55%. The purchase prices were between $39.23 and $55.82, with an estimated average price of $46.05. The stock is now traded at around $50.05. The impact to a portfolio due to this purchase was 0.5%. The holding were 906,600 shares as of .

Orbimed Advisors Llc added to a holding in Apellis Pharmaceuticals Inc by 438.93%. The purchase prices were between $12.81 and $19.82, with an estimated average price of $15.64. The stock is now traded at around $19.23. The impact to a portfolio due to this purchase was 0.47%. The holding were 1,762,300 shares as of .

Orbimed Advisors Llc sold out a holding in Allergan PLC. The sale prices were between $132.09 and $160.79, with an estimated average price of $144.95.

Orbimed Advisors Llc sold out a holding in CVS Health Corp. The sale prices were between $52.36 and $69.88, with an estimated average price of $61.96.

Orbimed Advisors Llc sold out a holding in Centene Corp. The sale prices were between $52.12 and $65.89, with an estimated average price of $60.76.

Orbimed Advisors Llc sold out a holding in UnitedHealth Group Inc. The sale prices were between $236.02 and $271.13, with an estimated average price of $255.35.

Orbimed Advisors Llc sold out a holding in bluebird bio Inc. The sale prices were between $99.2 and $160.74, with an estimated average price of $135.29.

Orbimed Advisors Llc sold out a holding in Molina Healthcare Inc. The sale prices were between $105.9 and $148.29, with an estimated average price of $134.96.

Orbimed Advisors Llc reduced to a holding in Biogen Inc by 89.5%. The sale prices were between $216.71 and $338.96, with an estimated average price of $315.3. The stock is now traded at around $236.43. The impact to a portfolio due to this sale was -4.31%. Orbimed Advisors Llc still held 87,700 shares as of .

Orbimed Advisors Llc reduced to a holding in Celgene Corp by 90.94%. The sale prices were between $64.09 and $94.34, with an estimated average price of $87.12. The stock is now traded at around $96.44. The impact to a portfolio due to this sale was -3.65%. Orbimed Advisors Llc still held 295,000 shares as of .

Orbimed Advisors Llc reduced to a holding in Cigna Corp by 47.67%. The sale prices were between $159.69 and $199.81, with an estimated average price of $183.17. The stock is now traded at around $153.13. The impact to a portfolio due to this sale was -0.84%. Orbimed Advisors Llc still held 252,600 shares as of .

Orbimed Advisors Llc reduced to a holding in Aerie Pharmaceuticals Inc by 93.35%. The sale prices were between $36.1 and $49.25, with an estimated average price of $43.86. The stock is now traded at around $39.98. The impact to a portfolio due to this sale was -0.56%. Orbimed Advisors Llc still held 58,000 shares as of .

Orbimed Advisors Llc reduced to a holding in argenx SE by 44.21%. The sale prices were between $96.07 and $134.59, with an estimated average price of $117.13. The stock is now traded at around $126.90. The impact to a portfolio due to this sale was -0.53%. Orbimed Advisors Llc still held 361,300 shares as of .

Orbimed Advisors Llc reduced to a holding in Puma Biotechnology Inc by 27.66%. The sale prices were between $20.35 and $42.37, with an estimated average price of $30.25. The stock is now traded at around $15.52. The impact to a portfolio due to this sale was -0.28%. Orbimed Advisors Llc still held 1,880,000 shares as of .